<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894137</url>
  </required_header>
  <id_info>
    <org_study_id>1355504-1</org_study_id>
    <nct_id>NCT03894137</nct_id>
  </id_info>
  <brief_title>The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE</brief_title>
  <official_title>The Acute Effect of Grains of Paradise (Aframomum Melegueta) on Resting Energy Expenditure in Lean, Healthy, Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexus Worldwide</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Plexus Worldwide</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator&#xD;
      pepper, belongs to the Zingiberaceae family, which is native to West Africa. GP seeds are&#xD;
      used as a spice and also have wide-ranging ethnobotanical uses. GP seeds are very rich in&#xD;
      non-volatile pungent compounds such as 6-paradol, 6-gingerol, 6-shogaol and related&#xD;
      compounds. This feature may equip them with the power to activate the Sympathetic Nervous&#xD;
      System and thereby increase EE, which has been demonstrated in rodents. Research suggest that&#xD;
      ingestion of GP extract can result in sustained elevation of EE and a consequent reduction in&#xD;
      body fat. Thus, there is some evidence that GP may have a potential thermogenic effect that&#xD;
      could be useful as part of a weight loss treatment. However, there is no information on&#xD;
      whether GP has the potential of improving and prolonging the thermogenic effects of&#xD;
      bioactives known to elevate fatty acid mobilization and subsequent fat oxidation. This&#xD;
      proposal will fill a void in the literature by testing for the first time in healthy, normal&#xD;
      weight, human volunteers whether the ingestion of GP in combination with a commercially&#xD;
      available complex containing caffeine, green tea, and forskolin has an enhanced acute effect&#xD;
      on REE, the largest and most stable component of EE, as well as the ratio of fat:carbohydrate&#xD;
      oxidation. This project will provide pilot data to support larger studies such as prospective&#xD;
      studies and studies to compare the thermogenic effect with currently available compounds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting metabolic Rate (Liters of oxygen consumed per minute)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Metabolic cart (metabolic gas exchange, indirect calorimitry)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting substrate oxidation</measure>
    <time_frame>3 weeks</time_frame>
    <description>Metabolic cart (respiratory exchange ratio)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heart Rate (beats per minute)</measure>
    <time_frame>3 weeks</time_frame>
    <description>pulse frequency over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure (mmHg)</measure>
    <time_frame>3 weeks</time_frame>
    <description>automatic blood pressure cuff</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Grains of Paradise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grains of Paradise (Aframomum Melegueta)</intervention_name>
    <description>This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism</description>
    <arm_group_label>Grains of Paradise</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18-65 years&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Able to provide written consent in English&#xD;
&#xD;
          -  A body mass index between 18.5 and 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Use of any prescribed or over-the-counter medication affecting metabolism&#xD;
&#xD;
          -  Suffering from cardiac, hepatic, renal, pulmonary, endocrine or hematological disease&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
          -  Consuming more than 300mg of caffeine per day&#xD;
&#xD;
          -  Consuming more than 2 alcoholic beverages per day.&#xD;
&#xD;
          -  Performing more than 3 hrs/week of strenuous exercise&#xD;
&#xD;
          -  Weight loss of more than 5% of body weight over the past 6 months&#xD;
&#xD;
          -  Not willing to abstain from alcohol, caffeine and exercise for 24hr before each test&#xD;
             day.&#xD;
&#xD;
          -  Suffering from heartburn or a sensitivity to pungent compounds in foods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grains of Paradise</keyword>
  <keyword>energy metabolism</keyword>
  <keyword>substrate oxidation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

